Rare dis­ease drug­mak­er Ul­tragenyx builds case for its gene ther­a­py fran­chise with fresh tri­al up­dates

Fo­cused on com­bat­ing a smat­ter­ing of rare dis­eases with an ar­se­nal of bi­o­log­ics, small mol­e­cules, and gene ther­a­pies, Ul­tragenyx Phar­ma­ceu­ti­cal this week is­sued some up­dates …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER